News & Industry Bulletins

Friday, May 6, 2022

Dominion Diagnostics Honored as One of the 2022 Best Places to Work in Rhode Island on the Company’s 25th Anniversary

Dominion Diagnostics was recently named as one of the 2022 Best Places to Work in Rhode Island. This marks the third year in a row, and sixth time overall, that Dominion has been recognized with this award.  

Wednesday, December 22, 2021

Dominion Diagnostics Earns Worksite Health Award for Commitment to Employee Health and Well-Being

Dominion Diagnostics was recognized with an Exemplary Worksite Health Award from Blue Cross & Blue Shield of Rhode Island (BCBSRI) and the Greater Providence Chamber of Commerce (the Chamber) for effective programs encouraging employee health and well-being in a meaningful way.

Wednesday, November 10, 2021

Dominion Diagnostics R&D Team Presents at ASMS2021

Dominion’s Research & Development team recently participated in the international conference for mass spectrometry, American Society for Mass Spectrometry or ASMS. Ana Grenier, Ph.D. was selected to present as one of the speakers where she presented a talk called "Strategies to Identify and Mitigate Interferences in Urine Drug Testing LC MS/MS Methods."

Thursday, March 21, 2019

Fight against fentanyl: Inside 1 town's opioid battle

Featured on The Today Show this morning - Fentanyl is a synthetic drug 50 times more potent than heroin, but it’s that potency that draws people to the dangerous opioid. NBC’s Kate Snow travels to Maine, where fentanyl is making rounds, to meet a dedicated group trying to beat it.

Friday, February 22, 2019

FDA Weighs Recommendation to Prescribe Naloxone Along With Opioids

CNN has reported that the U.S. Food and Drug Administration (FDA) is considering whether to recommend prescribing the opioid overdose antidote naloxone along with opioid prescriptions.

Monday, December 10, 2018

Dominion Diagnostics Establishes New Scholarship to Enhance Access to Vermont Recovery Residences

A new scholarship advancing addiction recovery in the state of Vermont has been established to support the Vermont Foundation of Recovery (VFOR) by Dominion Diagnostics, a leading national medical laboratory with a two-decade long history in the state and deep roots in its treatment and recovery community.

Tuesday, October 23, 2018

Dominion Diagnostics recognized for expanded testing launch and poised for new clinical research partnerships

Dominion Diagnostics is a well-respected, trusted healthcare company with over two decades of experience and expertise delivering patient-centered drug monitoring solutions, improved treatment outcomes and actionable clinical information to inform care.

Friday, August 31, 2018

Dominion Diagnostics employees observe International Overdose Awareness Day

Today, Rhode Island-based medical laboratory Dominion Diagnostics joined thousands of other organizations and individuals across the globe to commemorate International Overdose Awareness Day during an event held for its employees. The day itself demands urgent action and is aimed to raise awareness of overdose and reduce the stigma of a drug-related death.

Wednesday, March 21, 2018

Drugs Laced With Bug Spray Produce Zombie-Like Effects

Authorities in Indianapolis are concerned over an increase in overdoses of a street drug commonly known as KD that is laced with bug spray and produces zombie-like effects in users.

"We describe it as being like a zombie. They cannot talk to us," Indianapolis Fire Department Captain Chris Major told Indianapolis' FOX59 (WXIN-TV).

Thursday, January 18, 2018

Northeastern University features Dominion Diagnostics Director of Research and Development Lawrence Andrade in Recent News

Lawrence Andrade, UC’94, has to stay sharp to outpace street-drug kingpins. As the head of R&D at Dominion Diagnostics, a clinical toxicology lab and a leading maker of drug tests, Andrade’s job is to detect when people have drugs in their system. Not only does he have to stay on top of industry trends and technology, but he also has to keep an eye on the latest drugs to hit the streets. No small task, given the U.S. opioid epidemic, which has led to an explosion of drug abuse and lent new urgency to accurate drug testing.